2.3.1 STRENGTHS 8 2.3.2 WEAKNESSES 8 2.3.3 OPPORTUNITIES 8 2.3.4 THREATS 9 2.4 PRODUCT OFFERING 9 3.0 COMPETITIVE ANALYSIS 10 3.1 COMPETITORS 11 3.2 COMPETITOR ANALYSIS 12 4.0 SPECIFIC BUSINESS GROWTH OBJECTIVES 17 4.1 NICHE 17 4.2 STRATEGY 17 4.3 PROMOTION 17 5.0 FINANCIAL ANALYSIS 21 5.1 SALES PROJECTIONS 22 5.2 PROFIT AND LOSS STATEMENT 23 1.0 EXECUTIVE SUMMARY Sonal Holdings Kenya Limited was incorporated in 2002 and commenced operations
Words: 3078 - Pages: 13
http://news.bbcimg.co.uk/media/images/78427000/gif/_78427037_pharmaceutical_profits_624.gif http://adage.com/images/bin/pdf/WPpharmmarketing_revise.pdf http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/PharmExec-pharma50.pdf http://adage.com/images/bin/pdf/WPpharmmarketing_revise.pdf http://adage.com/images/bin/pdf/WPpharmmarketing_revise.pdf 2. Major factors of future growth The pharmaceutical
Words: 836 - Pages: 4
affecting the global pharmaceutical industry. PESTLE analysis used to help organisation to understand in depth that what is the current status of the organisation and the external factors which are effecting. It also helps to the Management to make strategy for the future and overcome the weak areas of the organization. - Political: Governments targeted this industry in their effort to avoid high healthcare costs. Strict regulations were established by them. Governments are very powerful and important
Words: 511 - Pages: 3
The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities December 2007 Michael Steiner, CFP®, CPA David H. Bugen, CFP®, MBA Brian Kazanchy, CFP®, CFA, MBA William T. Knox IV, CFP®, CFA, JD Margaret V. Prentice, MBA Lauren Goldfarb Mark P. Hurley Steven E. Cortez Christine L. Boudreaux Benjamin J. Robins Yvonne N. Kanner Shehzad Sippy Adam L. Bartkoski Ana M. Avila RegentAtlantic Capital, LLC Michael Steiner is a Wealth Manager and Principal with RegentAtlantic
Words: 43374 - Pages: 174
manage manufacturing in 7 countries and distribution in over 100. IMS Health estimated that Ranbaxy is among the top 100 pharmaceuticals in the world and that it is the 15th fastest growing company. By 2012, Ranbaxy hopes to be one of the top 5 generics producers in the world, and it consolidated its position with the purchase of French firm RGP Aventis in 2003. Ranbaxy also has higher aspirations, however, “to build a proprietary prescription business in the advanced markets.” To this end, it keeps
Words: 1204 - Pages: 5
Earnings per Share (EPS) increased from Rs. 64.9 in FY2011 to Rs. 83.8 in FY2012. I am particularly delighted by four developments. First, your Company succeeded in yet another blockbuster generic launch in the USA under 180days marketing exclusivity. Dr. Reddy’s launched olanzapine 20 mg tablets, the generic version of the brand Zyprexa®. Olanzapine is used to treat schizophrenia and bipolar disorder. This product has added around USD 100 million to your Company’s revenues for FY2012. Second, the
Words: 128176 - Pages: 513
Eli Lilly case questions 1) Did Eli Lilly pursue the right strategy to enter the Indian market? It was a right strategy for Eli Lilly that started a joint venture with Ranbaxy to enter the Indian market. First of all, Ranbaxy was the second largest pharmaceutical company that manufactures bulk drugs and generic drugs in India, with a domestic market share of 15 per cent. It had established broad distribution network, and it was the second largest exporter of all products in India. Ranbaxy’s
Words: 496 - Pages: 2
Bottom of Form |Read full version essay Case Analysis : Pharma Industry | |Case Analysis : Pharma Industry | |Print version essay is available for you! You can search Free Term Papers and College Essay
Words: 4303 - Pages: 18
also little by little becoming stronger and many of the big players were going through M&A processes that further increased the sales concentration in few companies. These companies had a hard time competing with local laboratories that produced generic drugs with no R&D expenses and at a fraction of the price. Eli Lilly Ranbaxy portraits the example of the traditional JV in which Ranbaxy, a company from less-industrialized country, offered the knowledge and distribution infrastructure of the local
Words: 1256 - Pages: 6
in Kava could be a great opportunity for the Teva Pharmaceuticals to expand its mission which is “to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals (TEVA USA., 2010, para 2)”. The company can expand that mission to the healthcare system of Kava Island highly vulnerable to many threats particularly storm, tsunami, earthquake, flood, fire, petroleum spills, AIDS/HIV, and avian flu
Words: 1991 - Pages: 8
